Cirrhotic cardiomyopathy: getting to the heart of the matter.
about
Cirrhotic cardiomyopathyCirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patientsDiastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesiaPathological impact of SMN2 mis-splicing in adult SMA micePrevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis.Cardiopulmonary dysfunction in cirrhosis.The Correlation between Echocardiographic Findings and QT Interval in Cirrhotic Patients.Cardiac dysfunction in cirrhotic portal hypertension with or without ascites.Liver transplantation for alcoholic liver disease.Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver diseaseDiastolic dysfunction characterizes cirrhotic cardiomyopathyCardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.Portopulmonary hypertension in decompensated cirrhosis with refractory ascitesIncreased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis.Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt.Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.Cardiac and vascular changes in cirrhosis: pathogenic mechanisms.Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.Therapy insight: Cirrhotic cardiomyopathy.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.Pathophysiological aspects of pulmonary complications of cirrhosis.Cardiovascular determinants of survival in cirrhosis.Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy.N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patientsEndocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.Cardiac and systemic haemodynamic complications of liver cirrhosis.Diastolic dysfunction and severity of cirrhosis in nonalcoholic cirrhotic patientsThe heart and the liver.Endocannabinoids and cardiac contractile function: pathophysiological implications.Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions.Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.Optimal management of hepatorenal syndrome in patients with cirrhosis.Cirrhotic cardiomyopathy: review of pathophysiology and treatment.Management of hepatorenal syndrome.Cardiac manifestations in alcoholic liver disease.The Relationship between QT Interval Dispersion and End-Stage Liver Disease Score in the Patients Undergoing Orthotopic Liver Transplantation.
P2860
Q26778048-A0D7764D-7490-4563-AD3A-4853C531DB96Q26826868-9F8C0E92-9421-4448-A78D-5B710F5AEC48Q30450624-D1C956AF-00CE-4DFC-9515-7AFD7FF5389CQ30551534-CCCF253D-88E9-4BB3-B58E-750E85E4B28AQ33562272-5324CB84-957E-4C3C-82F5-E34C7684D0B0Q33672187-9C123934-110A-457E-B3CB-C920A3CA7ADCQ33758733-359F7909-C996-46D1-9AE0-1623386104D2Q33813433-77861C02-95D0-4700-9F7D-CDE6D3013612Q34134927-038F4F93-5668-4415-9AD1-19C1149E0965Q34467402-34757FF0-66F5-4BFB-A972-2F6411CAB01AQ35028523-288C382B-BB2A-4E87-A350-42E49FA2BDCAQ35355011-D6F152CE-B428-4854-B210-75C470004127Q35595975-1D1D3769-5EF7-447D-A621-A1795EE1F142Q35596013-5C9489BE-7AEE-4FA8-981E-7AC76C2632FDQ35888758-46E92781-0BED-48F4-90F4-0D443E6BC5C1Q35953809-575627AA-F85D-45A2-B005-7F594E055DA2Q36203618-9DD3DEB5-924C-4141-9168-34D68AB17AA3Q36415452-C2C6327E-4792-4053-A898-9528E3305ADCQ36426811-B4BB01FA-3F5E-45E8-B4D9-FD676A8F91BBQ36495176-07EBBA55-C813-4957-9473-FD63D18CA421Q36772257-AD666CE5-4673-4941-AE70-C3AFED1C2805Q36799915-628212F7-B512-48E4-ADB9-DB4028F3EED2Q36829265-589C8629-E772-4AED-87D1-587B6413DFF6Q36909237-36F46A0C-6FD1-4D15-9F48-85E9A9F4FC40Q37040910-2CEB4A67-DB54-4D49-9BE8-4C74D4B5E0F7Q37243665-25E6B4FC-25F0-4A6E-8EAD-EC60071F9684Q37368987-5DF715F6-4AA9-472A-BDB7-3E05774EDFD7Q37385716-4776BF16-17D7-4336-971F-6BEC10418777Q37390649-ECB2DC22-07F2-4609-AE10-D70B36CA300BQ37401757-82065762-F2B3-4CF8-A93F-00F18F79E20DQ37771146-D6BC3631-A7BF-410B-A3A2-BA5C0CF7A096Q37903856-2BDF4724-E03A-4275-B640-887FA36EE776Q37980263-AA10277A-871D-4507-86CB-1FAF35AF8DF7Q38124458-FCD6914D-9558-4225-8EEF-FE4500D59162Q38133308-26A02017-3FD4-4AC4-B0FB-D4AE571ABB2DQ38173738-35F096AE-3817-45A7-A4C3-CF2EC1932357Q38249191-C932696C-E636-4AC0-8424-69811FB7AD9BQ38463841-D42DC5FA-7C23-4F0F-84DD-86D99FAA7052Q38724506-ACBB409D-5677-4BFB-B935-2090A2F0A1DDQ38764786-FCA6C83B-D441-4B05-B129-3A760A5C7DDA
P2860
Cirrhotic cardiomyopathy: getting to the heart of the matter.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Cirrhotic cardiomyopathy: getting to the heart of the matter.
@en
type
label
Cirrhotic cardiomyopathy: getting to the heart of the matter.
@en
prefLabel
Cirrhotic cardiomyopathy: getting to the heart of the matter.
@en
P356
P1433
P1476
Cirrhotic cardiomyopathy: getting to the heart of the matter.
@en
P304
P356
10.1002/HEP.510240226
P407
P577
1996-08-01T00:00:00Z